Stockscreener 앱 받기
12.08
1.26%
0.14
전일 마감가:
$11.94
열려 있는:
$12.08
하루 거래량:
75,530
Relative Volume:
0.03
시가총액:
$3.79B
수익:
$3.02B
순이익/손실:
$127.93M
주가수익비율:
54.59
EPS:
0.2213
순현금흐름:
$225.64M
1주 성능:
-9.44%
1개월 성능:
-20.41%
6개월 성능:
+25.81%
1년 성능:
+40.26%
1일 변동 폭
$12.04
$12.23
1주일 범위
$11.75
$13.22
52주 변동 폭
$6.685
$15.42
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.06 | 3.76B | 3.02B | 127.93M | 225.64M | 0.2213 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.39 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
120.97 | 49.87B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.52 | 46.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.58 | 34.31B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
535.27 | 23.42B | 3.18B | 1.33B | 1.04B | 27.90 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Retail Surge: Will Amneal Pharmaceuticals Inc benefit from green energy policies2026 Winners & Losers & Community Verified Swing Trade Signals - baoquankhu1.vn
Amneal Pharmaceuticals: Flattish 2026 Revenue Growth Aside, Stock Still Looks A Buy (AMRX) - Seeking Alpha
Algert Global LLC Cuts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory - MSN
Capula Management Ltd Buys New Shares in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Is Amneal Pharmaceuticals (AMRX) Pricing Reflect Its DCF Gap And Recent Share Slide - Yahoo Finance
Fed Meeting: Does Amneal Pharmaceuticals Inc stock have upside surprise potential2026 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Down 5.5%Here's What Happened - MarketBeat
Amneal Pharmaceuticals Inc (AMRX) Shares Gap Down to $12.73 on M - GuruFocus
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment - Yahoo Finance
What Amneal Pharmaceuticals (AMRX)'s Return to Profitability and 2026 Guidance Means For Shareholders - Sahm
Amneal Pharmaceuticals Conference: “Amneal 2.0” Targets 2026 Growth in Biosimilars, CREXONT and AvKARE Shift - MarketBeat
Amneal (AMRX) Stock Analysis 2026: Strong Gains vs. Future Growth ConcernsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Shorts Report: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdForecast Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
3 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Finviz
AMRX: Biosimilars and specialty launches fuel growth, with profitability and global expansion accelerating - TradingView
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Reassessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Long Term Returns And A High Current P/E Ratio - Sahm
Best Value Stocks to Buy for March 9th - The Globe and Mail
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus - MSN
Trade Report: Will Amneal Pharmaceuticals Inc benefit from current market trends2026 Big Picture & Verified Trade Idea Suggestions - baoquankhu1.vn
Citigroup Inc. Purchases 101,166 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by Quantbot Technologies LP - MarketBeat
Goldman Sachs Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal to Participate in Upcoming Investor Conference - National Today
Amneal (AMRX) EVP nets stock from RSU vesting and tax withholdings - Stock Titan
Amneal (AMRX) Co-CEO Chintu Patel gets major RSU and PSU grants - Stock Titan
Amneal (AMRX) Co-CEO awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) EVP awarded time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) CFO granted time- and performance-based RSUs - Stock Titan
Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP - Stock Titan
Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs - Stock Titan
AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amneal Pharmaceuticals, Inc. $AMRX Shares Purchased by Vanguard Group Inc. - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring A 19% Upside Potential - DirectorsTalk Interviews
Short Interest in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Drops By 16.4% - MarketBeat
Truist raises Amneal Pharmaceuticals stock price target on margin focus By Investing.com - Investing.com Canada
Truist raises Amneal Pharmaceuticals stock price target on margin focus - Investing.com
Truist Adjusts Price Target on Amneal Pharmaceuticals to $17 From $15, Maintains Buy Rating - marketscreener.com
Truist Financial Issues Positive Forecast for Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Price - MarketBeat
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments - simplywall.st
Earnings Miss: Can Amneal Pharmaceuticals Inc be the next market leaderQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
A Look At Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Envestnet Asset Management Inc. Takes $1.61 Million Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative - Sahm
The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release - simplywall.st
Earnings call transcript: Amneal Pharmaceuticals beats expectations in Q4 2025 - Investing.com Australia
Why Amneal (AMRX) Stock Is Trading Lower Today - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance - MarketBeat
Amneal Pharmaceuticals (NASDAQ: AMRX) grows biosimilars, Parkinson’s and injectables - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.13%
0.85%
자본화:
|
볼륨(24시간):